Mpa (Medroxyprogesterone Acetate)

Medroxyprogesterone acetate, the active ingredient in Mpa, is a progestogen presented as an oral tablet for oral use. It is employed to manage menstrual disorders, endometriosis, hormone‑replacement therapy, contraception and premenopausal symptoms in women.

GNH USA supplies Mpa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medroxyprogesterone acetate is a synthetic progestogen used in several hormonal pathways and conditions.

- Menstrual disorders: regulates irregular bleeding and alleviates dysmenorrhea. - Endometriosis: reduces ectopic endometrial tissue activity and associated pain. - Hormone replacement therapy: provides progesterone support in post‑menopausal regimens. - Contraception: suppresses ovulation and alters the endometrium to prevent pregnancy. - Premenopausal symptoms: mitigates hormonal fluctuations causing mood and physical symptoms.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Weight gain: increased appetite or fluid retention. - Headache: mild to moderate intensity. - Nausea: occasional stomach upset. - Breast tenderness: discomfort or swelling. - Mood changes: irritability or depressive feelings. - Menstrual irregularities: spotting or breakthrough bleeding.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: jaundice or elevated enzymes. - Depression or suicidal thoughts: significant mood alteration. - Adrenal suppression: signs of cortisol deficiency. - Unexplained vaginal bleeding: may indicate underlying pathology.

Before initiating therapy, consider the following safety measures.

- Assess thrombotic risk: evaluate history of clotting disorders. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Evaluate hormone‑sensitive cancers: avoid use in active breast or uterine cancer. - Avoid use in pregnancy unless clearly indicated: discuss risks with prescriber. - Review concomitant medications: check for potential interactions. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Medroxyprogesterone acetate can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Enzyme inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Antiretrovirals (e.g., efavirenz): may alter hormonal activity.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin): may modestly lower drug exposure. - Glucocorticoids: combined effect on adrenal axis. - Herbal supplements (e.g., St. John’s wort): may affect metabolism. - Other hormonal contraceptives: assess additive effects on clot risk. - Antifungal agents (e.g., fluconazole): may increase serum concentrations.